Skip to main content

Aktis Oncology, Inc.

corporate_fare Company Profile

Aktis Oncology, Inc.

AKTS·NASDAQ·Life Sciences·CIK 0002035832

Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company is developing next-generation technologies intended to broaden the cancer patient populations that can benefit from targeted radiopharmaceuticals by expanding the scope of tumor targets for which a powerful payload of an alpha-emitting radioisotope can be safely delivered. To ensure patient demand is reliably met, Aktis Oncology is also establishing efficient end-to-end supply through a combination of critical internal capabilities paired with established external vendors. Through these efforts, the company seeks to maximize clinical utility across multiple indications in multiple tumor types and to expand commercial uptake of radiopharmaceuticals beyond the traditional nuclear medicine setting into the more expansive clinical oncology setting. Aktis Oncology has built a proprietary miniprotein radioconjugate platform designed to safely confer breakthrough efficacy to a broad range of patient populations. Its miniprotein radioconjugates are designed to selectively deliver the tumor-killing properties of radioisotopes to targeted tumors with high tumor penetration and prolonged tumor retention, while being rapidly cleared from normal organs and tissues to minimize systemic radiation exposure. The company states that its miniproteins have demonstrated the ability to potently bind to tumor targets outside the scope of current delivery technologies such as peptide-based radioconjugates. The source notes that the field of targeted radiopharmaceuticals is currently led by two marketed products targeting prostate specific membrane antigen or somatostatin-2 receptor, each currently approved in only one tumor type, and that many emerging companies remain primarily focused on these same two targets.

Aktis Oncology, Inc. (NASDAQ:AKTS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for AKTS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for AKTS spans 8-K, 4, 10-Q, 10-K.

Recent high-impact activity:

  • Aktis Q3 Loss Widens to $29.9M; $492.9M Cash Funds Plan Into 2029
  • Aktis Oncology Starts Second Phase 1b Trial for AKY-2519 in Lung and Other Solid Tumors
  • COO Ron-Bigger Shulamit Exercises Options and Sells $1.39M in Aktis Stock
  • Aktis Oncology's AKY-2519 Radioconjugate Shows Robust Tumor Uptake, Limited Normal Tissue Exposure in Early Data
  • Aktis Oncology Reports Strong Q1 Results with $538.5M Cash, Extending Runway into 2029 Post-IPO

Short Interest & Short Volume

16.02 days to cover

FINRA reported short interest of 4,425,903 shares in AKTS as of the October 30, 2026 settlement, a 2.6% increase from the prior period — about 16.0 days to cover at its recent average daily volume. On November 20, 2026, 73.9% of AKTS volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)4,425,903 shares as of October 30, 2026
Change vs prior period▲ 2.6%
Days to cover16.02 at avg daily volume of 276,236
Daily short volume (FINRA facilities)73.9% of 121,388 shares on November 20, 2026
5-day average short volume79.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with A →
$16.46 +1.92% today
52-week range · as of 2026-11-12 $13.96 – $34.19
Market cap
$898.25M
Volume
375K (1.0× avg)
3-mo avg 378.5K
Live data · 2026-11-22 07:08 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed AKTS - Latest Insights

AKTS
Nov 12, 2026, 8:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $17.04
Real-time Price: $16.46 info
Change: -$0.580 (-3%) info
Market Cap: $898.255M info
AKTS
Oct 01, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $19.30
Real-time Price: $16.46 info
Change: -$2.84 (-15%) info
Market Cap: $898.255M info
AKTS
Jul 10, 2026, 6:11 AM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $28.50
Real-time Price: $16.46 info
Change: -$12.04 (-42%) info
Market Cap: $898.255M info
AKTS
May 21, 2026, 5:21 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $19.12
Real-time Price: $16.46 info
Change: -$2.66 (-14%) info
Market Cap: $898.255M info
AKTS
May 11, 2026, 4:06 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $18.27
Real-time Price: $16.46 info
Change: -$1.81 (-10%) info
Market Cap: $898.255M info
AKTS
May 11, 2026, 4:04 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $18.27
Real-time Price: $16.46 info
Change: -$1.81 (-10%) info
Market Cap: $898.255M info
AKTS
May 04, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $19.00
Real-time Price: $16.46 info
Change: -$2.54 (-13%) info
Market Cap: $898.255M info
AKTS
Apr 16, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $18.60
Real-time Price: $16.46 info
Change: -$2.14 (-12%) info
Market Cap: $898.255M info
AKTS
Mar 30, 2026, 5:29 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $16.54
Real-time Price: $16.46 info
Change: -$0.080 (-0.48%) info
Market Cap: $898.255M info
AKTS
Mar 30, 2026, 4:45 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $16.54
Real-time Price: $16.46 info
Change: -$0.080 (-0.48%) info
Market Cap: $898.255M info
AKTS
Jan 20, 2026, 5:44 PM EST
Filing Type: SCHEDULE 13D
Importance Score:
8
Price at Filing: $18.77
Real-time Price: $16.46 info
Change: -$2.31 (-12%) info
Market Cap: $898.255M info
AKTS
Jan 20, 2026, 2:01 PM EST
Filing Type: SCHEDULE 13D
Importance Score:
8
Price at Filing: $19.48
Real-time Price: $16.46 info
Change: -$3.02 (-15%) info
Market Cap: $898.255M info
AKTS
Jan 15, 2026, 6:02 AM EST
Filing Type: SCHEDULE 13D
Importance Score:
9
Price at Filing: $21.25
Real-time Price: $16.46 info
Change: -$4.79 (-23%) info
Market Cap: $898.255M info
AKTS
Jan 14, 2026, 6:20 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $20.82
Real-time Price: $16.46 info
Change: -$4.36 (-21%) info
Market Cap: $898.255M info
AKTS
Jan 14, 2026, 6:19 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $20.82
Real-time Price: $16.46 info
Change: -$4.36 (-21%) info
Market Cap: $898.255M info
AKTS
Jan 14, 2026, 6:17 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $20.82
Real-time Price: $16.46 info
Change: -$4.36 (-21%) info
Market Cap: $898.255M info
AKTS
Jan 14, 2026, 4:58 PM EST
Filing Type: SCHEDULE 13D
Importance Score:
8
Price at Filing: $21.00
Real-time Price: $16.46 info
Change: -$4.54 (-22%) info
Market Cap: $898.255M info
AKTS
Jan 12, 2026, 8:28 PM EST
Filing Type: 4
Importance Score:
9
Price at Filing: $22.44
Real-time Price: $16.46 info
Change: -$5.98 (-27%) info
Market Cap: $898.255M info
AKTS
Jan 12, 2026, 5:10 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $21.75
Real-time Price: $16.46 info
Change: -$5.29 (-24%) info
Market Cap: $898.255M info
AKTS
Jan 12, 2026, 5:00 PM EST
Filing Type: 4
Importance Score:
9
Price at Filing: $22.07
Real-time Price: $16.46 info
Change: -$5.61 (-25%) info
Market Cap: $898.255M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets